Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Advanced Squamous Non Small Cell Lung Cancer Clinical Trial

Official title: An Investigator-sponsored Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous Non-small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC

Clinical Trial Description

This two-stage phase 2 study will determine the safety, tolerability, recommended phase 2 dose/maximum tolerated dose, preliminary efficacy and predictive/pharmacodynamic biomarkers of combined EGFR inhibition (afatinib) and TNF inhibition (prednisone) in previously treated NSCLC. ;

Related Conditions & MeSH terms

• Advanced Squamous Non Small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

• NCT number: NCT04497584
• Study type: Interventional
• Source: University of Texas Southwestern Medical Center
• Contact: Sheena Bhalla, MD
• Phone: 214-648-4180
• Email: sheena.bhalla@utsouthwestern.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: August 4, 2021
• Completion date: September 1, 2025